News

Sort By

Over 2,400 Lipitor Diabetes Lawsuits Filed in Federal Court, More Expected

Courthouse columns

Lawsuits against Pfizer alleging that its blockbuster cholesterol drug Lipitor (atorvastatin) – a statin taken by millions of Americans – caused Type 2 diabetes continue to mount, as the first bellwether cases in federal multidistrict litigation (MDL) move closer to trial.

According to the latest report from the U.S. Judicial Panel on Multidistrict Litigation, more than 2,400 cases are pending before Judge Richard M. Gergel in the United States District Court for The District of South Carolina, Charleston Division. Plaintiffs assert that they developed Type 2 diabetes after taking Lipitor and must now face additional health risks and loss of quality of life. They claim Pfizer failed to warn them and misled consumers.

The first bellwether trials were selected in January 2015 and the first case to go to trial will be Daniels v. Pfizer (C.A. No. 2:14-1400). Wilma Daniels filed her lawsuit in February 2014, claiming Lipitor was “defective and unreasonably dangerous,” and accused Pfizer of “negligent and wrongful conduct,” according to the complaint.

Lawyers expect the number of Lipitor lawsuits in federal court to continue to rise. In the meantime, discovery and evidence continues to be presented in preparation for the first bellwether trial schedule to begin November 4.

Expert: Plaintiff Suffers from ‘Statin-Induced’ Type 2 Diabetes

Daniels was healthy prior to taking Lipitor and maintained a healthy weight and diet even after she began taking the drug in 1998 to reduce her risk of heart disease. However, she was diagnosed with Type 2 diabetes around 2004. As a result, she must now contend with an increased risk of heart disease, kidney damage, blindness, nerve damage and the stigma surrounding her diabetes, she states in her complaint against Big Pharma giant Pfizer.

Dr. David Handshoe, an expert for the plaintiff, provided a report stating that Daniels suffered from statin-induced Type 2 diabetes.

Lipitor, approved in 1996, is one of the best selling drugs of all time. The blockbuster drug has made Pfizer more than $131 billion since its release, and its sales peaked at $9 billion annually. Even after generics became available, Lipitor sales stayed strong thanks to aggressive marketing by the drug manufacturer, Forbes reported. And by 2015, the drug will still rake in about $3 billion.

FDA Warns of Statin Risks

Statin use is on the rise with about 30 million Americans using them. Doctors say about 27 million more should be using them. In addition, according to a study published in JAMA Internal Medicine Americans over 79 years of age use the most statins despite lack of clear guidelines for use in this group.

Just last year, the U.S. Food and Drug Administration (FDA) expanded their advice on statin use. While the agency still says the benefits outweigh the risks, the list of risks is still worthy of concern.

“Their benefit is indisputable, but they need to be taken with care and knowledge of their side effects,” said Amy G. Egan, M.D., M.P.H., deputy director for safety in FDA’s Division of Metabolism and Endocrinology Products (DMEP).

In addition to increased risk of high blood sugar and Type 2 diabetes, particularly in women, the FDA also cautioned that statins are linked to liver damage, memory loss and potential muscle damage.

Concerned patients shouldn’t simply stop taking their medication, however, the agency said. “Talk to your health care professional,” Egan said. “Don’t stop taking the medication. The consequences to your heart could be far greater.”

Last modified: April 3, 2017

Author

Michelle Y. Llamas is a senior content writer. She is also the host of Drugwatch Podcast where she interviews medical experts as well as patients affected by drugs and medical devices. She has written medical and legal content for several years — including an article in The Journal of Palliative Medicine and an academic book review for Nova Science Publishers. With Drugwatch, she has developed relationships with legal and medical professionals as well as with several patients and support groups. Prior to writing for Drugwatch, she spent several years as a legal assistant for a personal injury law firm in Orlando. She obtained her English – Technical Communication degree from the University of Central Florida. She is a committee member with the American Medical Writers Association.

Hide Sources

  1. Forbes. (2013, July 9). Pfizer's projected $3B drug: Name will shock you. Retrieved from http://www.forbes.com/sites/ycharts/2013/07/09/pfizers-projected-3b-drug-name-will-shock-you/
  2. Daniels v. Pfizer. (2014, February 25). In The United States District Court for The District of Colorado. Complaint. 2:14-cv-01400-RMG.
  3. MacGill, M. (2015, August 25). A third of very elderly Americans 'on statins without evidence.' Medical News Today. Retrieved from http://www.medicalnewstoday.com/articles/298492.php
  4. FDA. (2014). FDA expands advice on statin risks. Retrieved from http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM293705.pdf
  5. United States Judicial Panel on Multidistrict Litigation. (2014, August 17). MDL statistics report - distribution of pending MDL dockets by district. Retrieved from http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-August-17-2015.pdf